Shares of Novavax Inc. NVAX shed 2.41% to $7.68 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.35% to 18,285.16 ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

Novavax Inc. closed 67.02% below its 52-week high of $23.86, which the company achieved on June 6th.

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

BTIG initiated coverage of Novavax (NVAX) with a Buy rating and $19 price target The company’s standalone COVID vaccine seems to be a ...

GAITHERSBURG, Md., Feb. 27, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), today announced that the management team will participate in the following upcoming investor conferences: ...

Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a ...

Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships ...

Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...

Novavax (NVAX) stock jumped today following the release of the vaccine maker’s Q4 2024 earnings report. That follows its diluted earnings per ...

Novavax (NVAX) stock in focus as company beats Q4 revenue forecasts despite an 80% drop in product sales. Read more here.